Tag: KRAS

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global KRAS Inhibitors Market & Clinical Trials Forecast 2028” report has been added to ResearchAndMarkets.com‘s offering. The advancement in clinical research has led to the identification of several oncogenes that are generally mutated in cancers. Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated…

Continue Reading Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 – ResearchAndMarkets.com

A hypoxia-related signature in lung squamous cell carcinoma

Introduction Lung cancer is the major leading cause of tumour-related deaths throughout the world, while lung squamous cell carcinoma (LUSC) as the second most common histological type of lung cancer.1 Each year, almost 1.8 million people are diagnosed with lung cancer worldwide and 400,000 of these die from LUSC.2,3 Due to…

Continue Reading A hypoxia-related signature in lung squamous cell carcinoma

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer Single agent BMF-219 demonstrated pronounced anti-cancer activity…

Continue Reading Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Pandas merge rows with different operations for each column

import pandas as pd df = pd.DataFrame({‘case_id’:[‘1’, ‘1’, ‘1’,’2′,’2′,’2′], ‘Gene’:[‘KRAS’,’SMAD4′,’TP53′,’TP000′,’SMAD000′,’TP000′], ‘ch_a’:[0,1,0,0,0,0], ‘ch_b’:[0,0,0,1,1,0], ‘ch_c’:[0,0,0,1,1,0]}) case_id Gene ch_a ch_b ch_c 0 1 KRAS 0 0 0 1 1 SMAD4 1 0 0 2 1 TP53 0 0 0 3 2 TP000 0 1 1 4 2 SMAD000 0 1 1 5 2…

Continue Reading Pandas merge rows with different operations for each column

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping is noninferior to tissue-based genotyping for detection of guideline-recommended…

Continue Reading Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Non-genetic determinants of malignant clonal fitness at single-cell resolution

1. Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019). CAS  PubMed  Google Scholar  2. Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020). CAS …

Continue Reading Non-genetic determinants of malignant clonal fitness at single-cell resolution

BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

NEWARK, Calif., Sept. 22, 2021 /PRNewswire/ — BioChain Institute, (“BioChain”), a leader in high quality processed bio-sample products, announced an expanded line of Next Generation Sequencing (NGS) characterized bio-samples encompassing a variety of cancer-related mutations available for preclinical drug development and as reference samples for CLIA labs.  “Scientists are looking for…

Continue Reading BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

IRE combined with toripalimab versus IRE alone for LAPC

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…

Continue Reading IRE combined with toripalimab versus IRE alone for LAPC

A chink in lung cancer’s armor

The study of cancer is all about classification.  Tumors of the pancreas, breast or lung are further subdivided in classes, subclasses and sub-subclasses in order to understand their individual characteristics and devise specific therapies based on their unique sensitivities.  Lung cancer is broadly divided into two categories, small cell (SCLC)…

Continue Reading A chink in lung cancer’s armor

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing

Possible biomarkers for prognosis and clinical outcomes were identified, through the use whole exome sequencing and RNA sequencing, as therapeutic targets for patients with pancreatic ductal adenocarcinoma (PDAC), according to a recent study. The study, published in Therapeutic Advances in Medical Oncology, also reconfirmed genomic landscapes, major driver mutations, and…

Continue Reading Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing

Genomic Analysis of Lung Cancer in Never Smokers Identifies Three Molecular Subtypes

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body. The international team of scientists, led by researchers at the National Cancer Institute (NCI), carried out…

Continue Reading Genomic Analysis of Lung Cancer in Never Smokers Identifies Three Molecular Subtypes

Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Continue Reading Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Gene mutation analysis in papillary thyroid carcinoma

Introduction Thyroid tumors are the most common malignant tumors of the endocrine system, and their incidence has been increasing in the recent decades. Currently, there are some target drugs that can effectively treat PTC, and next-generation sequencing (NGS) can be used for targeted therapy. In order to make better informed…

Continue Reading Gene mutation analysis in papillary thyroid carcinoma

Doubts with Stacked barplot using R ggplot2

Doubts with Stacked barplot using R ggplot2 0 Hello! I am trying to plot some data using R but I am having some problems doing it. I have a data frame with two columns (genes and and type of mutation) and looks like: genes variant MLH1 Intronic ATR 5′ UTR…

Continue Reading Doubts with Stacked barplot using R ggplot2

ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

“…ctDNA may be more comprehensive representation of the tumor mutations of an individual patient,” the authors explained. “Longitudinal ctDNA analysis can also provide a molecular profile of how a tumor evolves and changes over time in response to chemotherapy.” They evaluated how the results of ctDNA analysis were associated with…

Continue Reading ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

Predicting and characterizing a cancer dependency map of tumors with deep learning

INTRODUCTION The development of novel cancer therapies requires knowledge of specific biological pathways to target individual tumors and eradicate cancer cells. Toward this goal, the landscape of genetic vulnerabilities of cancer, or the cancer dependency map, is being systematically profiled. Using RNA interference (RNAi) loss-of-function screens, Marcotte et al. (1),…

Continue Reading Predicting and characterizing a cancer dependency map of tumors with deep learning

GRCh37 GFF filter transcript isoforms by RefSeq Select tag or longest

GRCh37 GFF filter transcript isoforms by RefSeq Select tag or longest 0 Dear all, I tried to filter the “RefSeq Select” transcript isoforms in the GRCh37.p13 human genome annotation gff (GCF_000001405.25_GRCh37.p13_genomic.gff.gz). Specifically my goal is to retain for each gene a transcript isoform with a tag=RefSeq Select attribute if exists,…

Continue Reading GRCh37 GFF filter transcript isoforms by RefSeq Select tag or longest